About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
Be the most trusted biotech company
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2021-05-13
Henlius Will Release the RA Phase 3 Clinical Study Results of Its Rituximab Injection HLX01 at Two Congresses
2021-05-11
Henlius Entered into a Collaboration with NeuPharma of a BRAF Target Inhibitor
2021-05-10
Henlius will Release Two Clinical Studies of anti-PD-1 mAb Serplulimab in 2021 ASCO
2021-04-29
Biodrugs Published the Results of the International Multicentre Phase 3 Clinical Trial of 汉曲优®
2021-04-22
The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review
2021-04-20
Application for Clinical Trial of Henlius Bevacizumab HLX04-O Has Been Approved for the Treatment of wAMD in Latvia
2021-04-15
Henlius Received IND Approval for Its Novel Anti-LAG-3 mAb HLX26 from NMPA
2021-04-14
First Subject Dosed in Phase 1 Clinical Trial of Henlius COVID-19 Drug Candidate HLX71 in the US
2021-03-29
Making Most out of Launched Products, Fueling Diversified Innovation through Integrated Platform
1
2
3
4
5